Concurrent Inhibition of Akt and ERK Using TIC-10 Can Overcome Venetoclax Resistance in Mantle Cell Lymphoma

SIMPLE SUMMARY: Targeting BCL-2 through venetoclax is an effective therapy for a series of hematological cancers, such as mantle cell lymphoma (MCL), but resistance to venetoclax is an increasing challenge that needs to be overcome. In order to elucidate the resistance mechanisms to venetoclax in MC...

Descripción completa

Detalles Bibliográficos
Autores principales: Granau, Agnete Marie, Andersen, Pilar Aarøe, Jakobsen, Theresa, Taouxi, Konstantina, Dalila, Nawar, Mogensen, Johanne Bay, Kristensen, Lasse Sommer, Grønbæk, Kirsten, Dimopoulos, Konstantinos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856512/
https://www.ncbi.nlm.nih.gov/pubmed/36672458
http://dx.doi.org/10.3390/cancers15020510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856512/
https://www.ncbi.nlm.nih.gov/pubmed/36672458
http://dx.doi.org/10.3390/cancers15020510

Ejemplares similares